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Abstract   64 
Background: Effective treatment of  acromegaly with pegvisomant (PEGV), a growth hormone receptor 65 
antagonist, requires an appropriate dose titration. PEGV doses vary widely among individual patients, 66 
and various covariates may affect its dosing and pharmacokinetics.  67 
 68 
Objective: To identify predictors of the PEGV dose required to normalize insulin-like growth factor I (IGF-69 
I) levels during PEGV monotherapy and in combination with long-acting somatostatin analogues (LA-70 
SSAs).  71 
 72 
Design: Two retrospective cohorts (Rotterdam + Liège acromegaly survey (LAS), total n=188) were meta-73 
analysed as a form of external replication to study the predictors of PEGV dosing in addition to LA-SSA, 74 
the LAS (n=83) was used to study the predictors of PEGV monotherapy dosing. Multivariable regression 75 
models were used to identify predictors of the PEGV dose required to normalize IGF-I levels.  76 
 77 
Results: For PEGV dosing in combination with LA-SSA, IGF-I levels, weight, height and age, were 78 
associated with the PEGV normalization dosage (p=<0.001, p=<0.001, p=0.028 and p=0.047, 79 
respectively). Taken together, these characteristics predicted the PEGV normalization dose correctly in 80 
63.3% of all patients within a range of +/- 60 mg/week (21.3% within a range of +/- 20 mg/week). For 81 
monotherapy, only weight was associated with the PEGV normalization dose (p=<0.001) and predicted 82 
this dosage correctly in 77.1% of all patients within a range of +/- 60 mg/week (31.3% within a range of 83 
+/- 20 mg/week).  84 
 85 
Conclusion: In this study, we show that IGF-I levels, weight, height and age can contribute to define the 86 
optimal PEGV dose in order to normalize IGF-I levels in addition to LA-SSA. For PEGV monotherapy, only 87 
the patient’s weight was associated with the IGF-I normalization PEGV dosage.  88 
 89 




Acromegaly is a rare disease caused by excessive secretion of growth hormone (GH), and a subsequent 91 
increase in IGF-I production (1). The disease is almost exclusively caused by a GH-secreting pituitary 92 
adenoma (2). Severity and phenotype of the disease varies among acromegaly patients. Uncontrolled 93 
acromegaly is associated with an increase in morbidity and mortality (1). The control of IGF-I levels 94 
results in mortality rates similar to the general population (3). Although often unsuccessful in 95 
macroadenomas, transsphenoidal surgery generally is considered as the first treatment modality (4,5). 96 
Additional treatment after surgery is necessary when GH and IGF-I levels remain uncontrolled. Long-97 
acting somatostatin analogues (LA-SSAs), as adjuvant medical treatment or as primary medical 98 
treatment, are regularly prescribed. Several studies addressed the response of LA-SSA, and show that 99 
LA-SSA treatment alone reaches control of the disease in about 40% of the patients (6,7). A highly 100 
effective alternative for patients who are not normalized by LA-SSA monotherapy is the addition of 101 
pegvisomant (PEGV) to LA-SSA, or PEGV monotherapy, provided that the appropriate PEGV dose is given 102 
(8-12). PEGV is a PEGylated recombinant analogue of GH which competitively blocks the GH receptor, 103 
and thereby reduces the excessive GH actions in the liver and peripheral tissues (13,14). PEGV is slowly 104 
absorbed from the subcutaneous depot (Tmax of 33-77 hours, T1/2 el 74-172 hours) (15). The mode of 105 
PEGV-clearance is still not understood. We do not know whether the kidneys and/or the liver 106 
metabolizes the drug.    107 
 The dose of PEGV required to achieve disease control, defined as normalization of IGF-I levels, 108 
differs between individual acromegaly patients, both during PEGV monotherapy and in combination 109 
with LA-SSA (8,12). PEGV doses range widely between 20 – 200 mg/weekly during combination 110 
treatment with LA-SSA (16). A study by Freda et al. observed that patients using PEGV monotherapy in 111 
the ACROSTUDY with persistently elevated IGF-I levels needed a higher mean PEGV dosage (17). 112 
Defining the optimal starting dose for PEGV is difficult as the pharmacokinetics remain to be elucidated 113 
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and data on pre-treatment determinants of the PEGV dosage required for biochemical disease control is 114 
sparse. Currently, IGF-I levels are most commonly used during PEGV titration, which is in line with a 115 
previous study from our group reporting a positive correlation between baseline IGF-I levels and the 116 
PEGV dose required for normalization of IGF-I during combination treatment of LA-SSA and PEGV (8,18). 117 
Other predictors that have been reported are GH levels, sex, body weight and previous radiotherapy 118 
(19,20). Two studies previously reported about a GH receptor polymorphism lacking exon 3, which 119 
seemed to have an influence as well during PEGV dosing (21,22). However more recent studies in larger 120 
acromegaly cohorts clearly state that this polymorphism has no clinical effect on the PEGV response nor 121 
the determination of the required PEGV dose (23-25).  122 
  Given the importance of swift biochemical control in acromegaly but the lack of studies 123 
investigating pre-treatment predictors we aimed to develop a multivariate regression model for 124 
predicting the required PEGV dose to achieve normalization of IGF-I levels in acromegaly patients.  125 
 126 
Materials & Methods 127 
Cohorts description 128 
Patients (n=271) were included from two retrospective cohorts; 1) the Rotterdam cohort and; 2) the 129 
Liége acromegaly survey (LAS) cohort (26). The Rotterdam cohort contains data from acromegaly 130 
patients using LA-SSA in combination with PEGV (n=112) collected in the Pituitary Center Rotterdam 131 
between 2004 and 2013, previously published in 2014 (8). The LAS cohort (n=3194 from 14 centers), was 132 
created using a software tool which enables hospitals throughout Europe to include acromegaly patients 133 
and report patient, biochemical and adenoma characteristics (26). For this study, only patients using 134 
PEGV monotherapy (n=83) or PEGV in combination with LA-SSA (n=76) were enrolled from 10 different 135 
centers. The inclusion period was between 2010 and 2015.   136 
 137 
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Rotterdam cohort 138 
Clinical and biochemical data were collected from acromegaly patients with elevated IGF-I levels (>1.2x 139 
upper limit of normal (ULN)), after at least 6 months of the highest dose of LA-SSAs (octreotide LAR 30 140 
mg or lanreotide Autogel 120 mg every 28 days). In this group, 27 acromegaly patients started with 25 141 
mg PEGV weekly as co-treatment, while another 18 started with 40 mg PEGV weekly, and the last 67 142 
patients started with a variable PEGV dose, guided by their baseline IGF-I levels. This variable PEGV 143 
starting dose was based on one of our previous reports (figure 2, (18)). The formula to calculate the 144 
PEGV dose is 4 + (IGF-I z-score during treatment with high dose LA-SSA*16) and was deducted from a 145 
method described previously (18). This formula can only be used when IGF-I levels are elevated after a 146 
period of at least 6 months of LA-SSA treatment. Intervals of dose adaptations were 6-8 weeks until a 147 
controlled IGF-I level was achieved on two consecutive occasions. The subjects then visited our 148 
outpatient clinic every 16 weeks. When the once weekly PEGV dose exceeded 80 mg per injection, 149 
patients divided the dosage to two weekly injections. With weekly doses over 200 mg, subjects changed 150 
administration intervals into daily injections or 5 injections per week. At each visit to our outpatient 151 
clinic, standard measurements were performed including assessments of IGF-I levels. Permission from 152 
the Institutional Review Board of the Erasmus Medical Center Rotterdam was obtained and all patients 153 
gave their written informed consent. 154 
 155 
LAS cohort 156 
Acromegaly patients from the LAS database treated with PEGV were selected and divided in two groups; 157 
PEGV in combination with LA-SSA and PEGV monotherapy. From the LAS-database, we were able to 158 
select 141 potential patients using the combination treatment. We excluded 65 patients, because of two 159 
reasons; 1) no IGF-I normalization during LA-SSA + PEGV treatment was achieved (n=16) and; 2) follow-160 
up data during LA-SSA/PEGV-treatment were missing (n=49). The remaining patients (n=76) were 161 
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selected for this study. The same exclusion criteria applied for the PEGV monotherapy patients. We 162 
were able to select 122 potential patients using PEGV monotherapy. We excluded 39 patients (no IGF-I 163 
normalization during PEGV monotherapy was achieved (n=6) and follow-up data during PEGV-treatment 164 
were missing (n=33)). The remaining patients (n=83) were selected for this study. The medical ethics 165 
committee from the Liège University hospital approved the protocol, and was covering the other 166 
European centers.   167 
 168 
Hormone assays 169 
In the Rotterdam cohort, the GH and IGF-I level measurements were assessed with the Immulite 2000 170 
assay (DPC Biermann GmbH/Siemens, Fernwald, Germany), a solid-phase, enzyme-labeled 171 
chemiluminescent immunometric assay, with an intra-assay variability of 6%, and an inter-assay 172 
variability of 5-6% for GH and with an intra-assay variability of 2-5%, and an inter-assay variability of 3-173 
7% for IGF-I. The IGF-I age and sex-adjusted reference ranges were used from an article by Elmlinger et 174 
al. (27). In the LAS cohort, containing acromegaly patients from several European hospitals, the GH and 175 
IGF-I level measurements were assessed locally, and consequently performed with different assays. 176 
Therefore, the IGF-I levels were chosen to be expressed as the upper limit of normal (ULN) of the 177 
reference ranges used in the local hospitals. In this study, GH levels were measured as a single random 178 
sample and expressed as absolute values.  179 
 180 
Candidate predictors 181 
Variables that were considered as possible predictors for PEGV normalization dosage were selected 182 
based on the literature (8,18-20), biological plausibility, and availability of robust data ascertainment in 183 
both cohorts and included: age at diagnosis, sex, weight, height, tumor size (micro vs. macroadenoma at 184 
diagnosis), presence of diabetes mellitus, IGF-I levels (expressed as ULN), random GH levels and previous 185 
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treatment modalities (transsphenoidal surgery, radiotherapy and the duration of LA-SSA monotherapy 186 
before the addition of PEGV). Weight, IGF-I levels (expressed as ULN) and random GH levels were 187 
collected between 6 months before and at the time of PEGV-addition. Other data was collected at 188 
baseline (as indicated), was fixed data in the patient’s record, or was established during disease process.  189 
 190 
Outcome 191 
The outcome used in this study was the PEGV dose (mg/week) needed for the normalization of IGF-I 192 
levels either during the addition to LA-SSA (highest tolerable dose) or as PEGV monotherapy.  193 
 194 
Statistical analysis:  195 
Data are expressed as median [interquartile range]. Differences between two subgroups were analysed 196 
using an unpaired t-test or the Mann-Whitney U test (in case of non-parametric data). Nominal variables 197 
were analysed using Fisher’s exact test. For subjects in which PEGV was added to LA-SSA therapy, the 198 
distribution of the PEGV dose required for normalization of IGF-I levels was not comparable between 199 
the two cohorts, therefore we meta-analyzed the data as a form of external replication. For all 200 
regression models, log-transformation of the outcome variable (required PEGV dose) was performed to 201 
normalize residuals and non-linearity was assessed utilizing restricted cubic splines with 3-4 knots. We 202 
used univariable linear regression models to assess the association between each candidate predictor 203 
and the required PEGV dose. The decision for linear regression models instead of multiple models for 204 
the identification of predictors was based on Akaike information criterions and log-likelihood tests 205 
comparing multilevel models with random intercepts and/or slope per cohort versus standard linear 206 
regression correcting for cohort. To allow for optimal generalizability of effect estimates that predict the 207 
required PEGV dose, we performed multivariable multilevel modelling with a random intercept per 208 
cohort for the final model. We selected useful predictors using backward selection based on the change 209 
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in regression coefficients and residual explained variability of the model, with a p-value <0.20 as to keep 210 
predictors liberally in the model. Other p-values are considered statistically significant when lower than 211 
0.05 (two-tailed). For subjects switching from LA-SSA to PEGV monotherapy, we used univariable linear 212 
regression models to assess the association between each potential predictor and the required PEGV 213 
dose. We subsequently calculated the predicted normalization dosage for each subject using the 214 
outcomes of the final (multivariable) regression models. In addition, we also calculated more 215 
conservative and more progressive models to cope with potential under or overtreatment by adding or 216 
subtracting the equivalent of 40 mg/week from the outcome of the regression formula. To cope with 217 
(differentially) missing values of the candidate predictors, missing data on candidate predictors were 218 
multiple imputed (five times). The imputation model included all candidate predictor variables, the 219 
outcome variable and several relevant variables descriptive for the study subjects. There was no 220 
difference between the original or any of the imputed datasets. All analyses were performed in each of 221 
the completed datasets and final results were pooled. All statistical analyses were performed using 222 
Statistical Package of Social Sciences version 20.0 for Windows (SPSS Inc. Chicago, IL, USA) or using R 223 
statistical software version 3.2.43 (packages rms, MASS and lm4). 224 
 225 
Results 226 
Cohort characteristics 227 
Patient characteristics and previous treatment modalities of the two combination treatment cohorts 228 
and the PEGV-monotherapy cohort are depicted in table 1. Acromegaly patients treated with the 229 
combination treatment included in the LAS-database are younger (39.0 vs. 45.5 years), more likely to be 230 
diagnosed with a macroadenoma (90.8% vs. 81.3%) and suffered from diabetes mellitus more frequently 231 
(43.4% vs. 36.6%). Patients from the Rotterdam cohort are taller (178 vs. 170 cm). Patients who were 232 
included in the LAS-database needed higher PEGV doses in order to achieve normalized IGF-I levels both 233 
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during combination treatment with LA-SSA and during PEGV monotherapy and had a higher IGF-I level 234 
(xULN) before the addition of PEGV. Other descriptive data and measurements such as weight, height, 235 
and biochemical data are depicted in table 1, as well as comparisons between the combination 236 
treatment group and the PEGV monotherapy group.  No significant differences were observed in the 237 
combination treatment cohort between excluded (all originated from the LAS database) and included 238 
patients, except for the percentage of performed surgeries, radiotherapy and height, the excluded 239 
patients were smaller in stature. No significant differences were observed in the PEGV monotherapy 240 
cohort between excluded and included patients.  241 
 242 
Predictors of PEGV dosing  required for disease control in combination treatment with LA-SSA  243 
All univariate analyses of the candidate predictors are depicted in figure 1. A positive linear association 244 
was observed between IGF-I (xULN) and the PEGV dosage required for disease control. There was a 245 
positive non-linear association of weight with PEGV normalization dosage, suggesting an effect 246 
threshold from approximately 100 kg (figure 1), results were similar after adjustment for age and height 247 
(data not shown). There was a negative linear association of age with PEGV normalization dosage and a 248 
positive linear association of height with PEGV normalization dosage. In multivariable analyses, the 249 
association of age and height were no longer statistically significant after adjustment for weight, yet age 250 
did meet the pre-specified criteria of being added in the final model. Other potential predictors were 251 
not associated with the PEGV normalization dosage (figure 1). 252 
 Figure 2 depicts the performance of the standard prediction model (x-axis) as compared to the 253 
true PEGV normalization dosage (y-axis) and the difference between the predicted and true 254 
normalization PEGV-dose for each individual (colored dots are corresponding to the table colors; figure 255 
2). The standard prediction formula for PEGV normalization dosage based on multivariable models 256 
(EXP^(5.5994 + IGF-1 ULN*0.2585 + weight*-0.0365 + weight2*0.00025 + age*-0.0045)) (table 2) 257 
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predicted the final PEGV normalization dose correctly in 63.3% of all patients within a range of +/- 60 258 
mg/week and in 21.3% of all patients within a range of +/- 20 mg/week (figure 2). In addition, a more 259 
conservative model (standard prediction model minus 40 mg/week) correctly predicted the PEGV 260 
normalization dosage in 66.4% of all patients within a range of +/- 60 mg/week, and in 34.0% of all 261 
patients within a range of +/- 20 mg/week (figure 2). For a more progressive model (standard model plus 262 
40 mg/weekly), these numbers were 37.7% and 8.5%, respectively (Figure 2). 263 
 264 
Predictors of PEGV dosing  required for disease control during PEGV monotherapy   265 
A positive linear association was observed between weight and the PEGV dosage required for disease 266 
control (p=<0.001; figure 3 and figure 4). None of the other potential predictors were associated with 267 
the PEGV normalization dosage (figure 3). Figure 4 depicts the performance of weight (x-axis) as a 268 
predictor for PEGV normalization dosage as compared to the true normalization dosage (y-axis) and the 269 
difference between the predicted and true normalization dosage for each individual (colored dots are 270 
corresponding to the table colors; figure 4). The standard prediction formula for PEGV normalization 271 
dosage based on weight (EXP^(4.092 + weight*0.00868)) predicted the final PEGV normalization dose 272 
correctly in 77.1% of all patients within a range of +/- 60 mg/week and in 31.3% of all patients within a 273 
range of +/- 20 mg/week (figure 4). In addition, a more conservative model correctly predicted the PEGV 274 
normalization dosage in 67.4% of all patients within a range +/- 60 mg/week, and in 32.5% of all patients 275 




The PEGV dose required for normalization of IGF-I levels in acromegaly is highly variable and a wide 280 
inter-individual variation in PEGV serum levels is observed despite identical PEGV dosage (28,29).  281 
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Previous studies suggest that this variability depends on disease activity and individual response to the 282 
drug (8,16). Therefore, PEGV titration is a process that requires a tailored approach for each individual. 283 
This is the first study that focuses on identifying predictors for PEGV dosing and developing a 284 
multivariable model in order to predict the required PEGV dose to achieve normalization of IGF-I levels 285 
in acromegaly patients. The main findings of this study are; 1) IGF-I, weight, height and age at diagnosis 286 
are associated with the PEGV dose required for normalization of IGF-I levels in patients treated with LA-287 
SSA combined with PEGV and; 2) that weight is associated with the PEGV dose required for 288 
normalization of IGF-I levels in patients treated with PEGV monotherapy.  289 
 To the best of our knowledge, only one previous study has investigated determinants of the 290 
PEGV dose needed for IGF-I normalization. Parkinson et al. observed that GH and IGF-I levels, sex, 291 
weight and previous radiotherapy were associated with the PEGV dose required for disease control in 292 
patients treated with PEGV monotherapy (n=118)  (20). In our study, IGF-I xULN was the best predictor 293 
for PEGV dosing, yet GH levels were not associated with the required PEGV dose. The most likely 294 
explanation for this difference is the variability of the GH-assays. The study by Parkinson et al. used a 295 
single assay for the measurement of all GH levels, while GH levels in our study were measured in several 296 
local hospitals and thereby consequently measured by different GH-assays. This can lead to 297 
measurement errors and a bias. Moreover, single GH has a limited clinical usefulness as it has a short 298 
half-life and is pulsatile excreted into the bloodstream. Therefore random single measurements of GH 299 
are less suitable as a biochemical marker for acromegaly in clinical practice. These aspects are less 300 
prominent  for IGF-I measurements, as they are expressed as the upper limit of normal and are less 301 
sensitive to daily variations as compared to GH. Despite, the limitations of GH-measurement, we chose 302 
to include and analyze these GH levels, because of its biological plausibility as a candidate predictor and 303 
the intension that our prediction model is going to be used in multiple hospitals and consequently GH-304 
measurements will be performed with several different assays.  305 
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The best predictor during combination treatment, besides IGF-I, is the patients weight before 306 
the start of PEGV. Patients with a higher bodyweight, require a higher PEGV dosage, which is a logical 307 
and expected phenomenon. However in our study a positive non-linear association was observed, 308 
suggesting a threshold effect from approximately 100 kg body weight which remained similar after 309 
correction for sex, age and IGF-I levels. A possible explanation for this effect threshold could be that 310 
these patients have different disease activity and therefore have a different body composition, possibly 311 
more fat mass. Former studies already reported an association between weight and PEGV dose titration 312 
(19,20,30). Future studies should investigate whether a clinical assessment of body composition (ratios 313 
of lean vs. fat mass percentages) may improve the prediction of the PEGV dose required for biochemical 314 
normalization.  315 
Female gender is reported to have a better PEGV response with similar PEGV doses during PEGV 316 
monotherapy, however this gender-difference was not statically significant anymore when PEGV doses 317 
were expressed per kg body weight (19). Another study did observe that women needed a higher 318 
average PEGV dose of 0.04 mg/kg/day during PEGV monotherapy (20). It has been speculated that sex 319 
differences in PEGV pharmacokinetics may influence absorption, distribution and/or clearance of the 320 
drug as well as the modulation of GH sensitivity by estrogens and fat (31-33). However, regardless of 321 
weight differences, we could not confirm a sex difference in relation to the PEGV normalization dose 322 
during our study both in patients treated with PEGV monotherapy and in combination with LA-SSA.  323 
Opposite to patients treated with the combination therapy, we found that IGF-I was not a 324 
predictor of PEGV dosing during PEGV monotherapy, despite its biological plausibility. This may be 325 
explained by differences in the disease severity of patients in the combination versus monotherapy 326 
groups, given that the LAS combination cohort requires a median PEGV dose of 210 mg/week on top of 327 
the maximum LA-SSA dosage, while the LAS cohort treated with PEGV monotherapy required a median 328 
dose of 105 mg/week. According to the literature, to achieve efficacy rates of more than 90% during 329 
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PEGV monotherapy, the average expected weekly dose is above 120-130 mg (12,34). Studies about the 330 
combination treatment reported PEGV doses that range between 60-140 mg weekly in addition to LA-331 
SSA (normalization rates range between 67-97%) (8,10,35). These data show that the LAS-monotherapy 332 
group contains less severe acromegaly patients, while the LAS-combination treatment group contains 333 
more severe acromegaly patients relative to data from the literature, presumed that the PEGV dose 334 
represents disease severity. On the other hand, LA-SSA has a direct and an indirect effect, which results 335 
in GH-independent decrease of IGF-I secretion (36,37). A Danish group observed that PEGV serum levels 336 
increase by 20% when combined with LA-SSA (38). Besides dosing difference, it may be expected that 337 
the use of two drug modalities is naturally more given to patients with more disease severity. 338 
Additionally, IGF-I (xULN) levels before the addition of PEGV in both LAS cohorts treated with 339 
monotherapy and combination treatment are higher. On the other hand, it should be take into account 340 
the differences between the various IGF-I-assay’s which were used in the different cohorts.  341 
The PEGV doses of the LAS cohort required for IGF-I normalization were strikingly high 342 
compared to the Rotterdam cohort. The distribution of normalization PEGV dosage were right skewed 343 
as opposed to the normally distributed Rotterdam cohort. This most likely reflects the fact that the LAS 344 
cohort represents the more severe cases in Europe, while the experience with PEGV in Rotterdam has 345 
led to a relatively low threshold for prescribing  PEGV in addition to LA-SSA. This may not directly be 346 
linked to a difference in IGF-I levels before the addition of PEGV in our study, however LAS patients are 347 
younger and are having more diabetes mellitus, which are characteristics of more severe acromegaly. 348 
Another possible explanation could be the interest of the research group in Liège for genetic disorders 349 
causing acromegaly, taking into account that the possible prevalence of a mutation in the aryl 350 
hydrocarbon receptor interacting protein (AIP) gene, X-linked acrogigantism (X-LAG) and/or familial 351 
isolated pituitary adenoma (FIPA) patients could be higher in this cohort. Despite these differences, we 352 
found that a meta-analysis of both cohorts (as a form of external replication) performed well and also 353 
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the separate analyses per cohort showed the same effect directions. By combining both cohorts, the 354 
results of this study are widely generalizable as this approach has led to a study population that reflects 355 
a wide range of acromegaly patient that is eligible to start PEGV treatment.  356 
 This study was potentially limited by the retrospective design, which consequently led to missing 357 
data. In order to cope with both differentially and randomly missing data, we used multiple imputation. 358 
This study was also limited by the relative small sample size. However, this is expected given the low 359 
prevalence  of acromegaly as well as the fact that only a subset of acromegaly patients is treated with 360 
LA-SSA in combination with PEGV. The Rotterdam cohort harbored exclusively patients that were 361 
normalized by LA-SSA in combination with PEGV, as PEGV doses were up-titrated until normalization of 362 
IGF-I levels were achieved. The exclusion of patients from the LAS cohort not normalized by LA-SSA and 363 
PEGV (n=16, 8.5%) or PEGV alone (n=6, 7.2%) has remained limited. In order to overcome these 364 
limitations and to replicate our results, prospective studies utilizing a multicenter set-up are required.  365 
This model is designed  for patients who are about to start PEGV treatment after failure of LA-366 
SSA monotherapy. Furthermore, this study is not designed to predict PEGV overdosing, since PEGV 367 
doses were increased until IGF-I levels were normalized. But this prediction model should be considered 368 
as a useful clinical tool during PEGV dose titration, which can be time consuming over multiple 369 
outpatient clinic visits, especially when a high PEGV dose is needed to control the disease.   370 
 371 
Conclusion 372 
This is the first study that focuses on identifying predictors for the PEGV dose required for disease 373 
control in acromegaly and the development of a multivariate prediction model for the required PEGV 374 
dose. The model is designed for patients who are about to start PEGV after failure of LA-SSA 375 
monotherapy and could be used as a clinical guidance tool during the start of PEGV dose titration. In this 376 
study, the PEGV dose needed for normalization of IGF-I levels in addition to LA-SSA is associated with 377 
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IGF-I levels, weight and age in a multivariate prediction model and predicted the final PEGV 378 
normalization dose correctly in 63.3% of all patients within a range of +/- 60 mg/week (21.3% within a 379 
range of +/- 20 mg/week). The required PEGV dose during monotherapy was associated with the 380 
patient’s weight and predicted the final PEGV normalization dose correctly in 77.1% of all patients within 381 
a range of +/- 60 mg/week (31.3% within a range of +/- 20 mg/week). For an acromegaly patient of 60 382 
years old, weight of 80 kilograms, height of 1.75 meters, and a IGF-I level of 1.6x the ULN using the 383 
maximum dose of LA-SSA, the standard model will calculate 83.3 mg PEGV weekly. In this case, we will 384 
recommend to start with 80 mg weekly and titrate up or down guided by the IGF-I level (target 1.0x the 385 
ULN).  386 
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Tables and figures 523 
Table 1. Descriptive characteristics of the combination treatment and PEGV monotherapy cohorts  524 
Descriptive characteristics of the three cohorts: Rotterdam cohort using LA-SSA + PEGV, LAS cohort using LA-SSA + PEGV and the LAS cohort 525 
using PEGV monotherapy. Missing data were imputed in the original datasets by multiple imputation. Continues variables are expressed in 526 
median [interquartile range] and categorical variables in percentages. LA-SSA: long-acting somatostatin analogues, PEGV: pegvisomant, LAS: 527 
Liège acromegaly survey, kg: kilogram, cm: centimeter, Macro: Macroadenoma, IGF-I: insulin-like growth factor I, GH: growth hormone, RTx: 528 
radiotherapy, mg: milligram, N/A: not applicable. 529 
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a) Combination treatment (Rotterdam)  vs. combination treatment (LAS) 530 
b) Combination treatment (Rotterdam and LAS)  vs. PEGV monotherapy (LAS) 531 
 532 
Figure 1. Identification of potential predictors during combination treatment 533 
 534 
Figures are provided separately 535 
 536 
Univariate analyses of multiple determinants potential for the prediction of the PEGV dose needed to achieve normalization of IGF-I levels 537 
during combination treatment. IGF-I xULN, age at diagnosis, weight and height were significantly associated with PEGV dosing during PEGV 538 
treatment in combination with LA-SSA. PEGV: pegvisomant, IGF-I: insulin-like growth factor I, ULN: upper limit of normal, GH: growth hormone, 539 





Table 2. Multivariable analysis of final model to predict optimal PEGV dosing 545 
 546 
As the outcome is not normally distributed, the model should be calculated as: е
(final model)  547 
*before the addition of PEGV to LA-SSA. PEGV: pegvisomant, SE: standard error,  548 
IGF-I: insulin-like growth hormone I, ULN: upper limit of normal.  549 
 550 
 551 
Figure 2. Association of combined predictive values with the PEGV dose needed for IGF-I normalization 552 
 553 
Figures are provided separately 554 
 555 
This figure shows the association of the combined predictive values (X-axis,  the model) with the PEGV dose needed for IGF-I normalization as 556 
obtained in clinical practice (Y-axis). The regression line is represented by the dashed line (grey). The individual data-points are colored 557 
according to the distance from the regression line (red: distance = 60 mg/week, orange 20-60 mg/week, green <20 mg/week). Data-points in 558 
the figure depict the standard model. The conservative and progressive model were defined as the normal model minus or plus 40 mg/week, 559 
respectively. The table below depicts the n (%) of the different model groups and also display the potential shift between the models. 560 
 561 
 562 
Figure 3. Identification of potential predictors during PEGV monotherapy 563 
 564 
Figures are provided separately 565 
 566 
Univariate analyses of multiple determinants potential for the prediction of the PEGV dose needed to achieve normalization of IGF-I levels 567 
during PEGV monotherapy. Only weight was significantly associated with PEGV dosing during PEGV monotherapy. PEGV: pegvisomant, IGF-I: 568 
insulin-like growth factor I, ULN: upper limit of normal, GH: growth hormone, micro: microadenoma, macro: macroadenoma.  569 
 570 
 571 
Figure 4. Association of weight with the PEGV dose needed for IGF-I normalization 572 
 573 
Figures are provided separately 574 
 575 
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This figure shows the association of the patient’s weight  (X-axis) with the PEGV dose needed for disease control as obtained in clinical practice 576 
(Y-axis). The regression line is represented by the dashed line (grey). The individual data-points are colored according to the distance from the 577 
regression line (red: distance = 60 mg/week, orange 20-60 mg/week, green <20 mg/week). Data-points in the figure depict the standard model. 578 
The conservative and progressive model were defined as the normal model minus or plus 40 mg/week, respectively. The table below depicts 579 
the n (%) of the different model groups and also displays the potential shift between the models. 580 
 581 
 582 
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Combination treatment 







 Total cohort Rotterdam LAS  LAS  
No. of patients 188 112 76  83  
Patient characteristics:        
Age at diagnosis 42.0 [33.0 – 53.0] 45.5 [36.0 – 56.0] 39.0 [29.5 – 47.0]  0.000 41.0 [29.0 – 51.0]  0.001 
Sex – Male % 58.0 58.0 57.9 1.000 53.0 0.000 
Weight before addition of PEGV – kg 90.0 [77.0 – 104.0] 91.5 [79.0 – 104.0] 89.0 [74.5 – 105.0] 0.107 83.0 [71.0 – 93.0] 0.000 
Height before addition of PEGV – cm 175.0 [168.0 – 182.0] 178.0 [170.0 – 184.0] 170.0 [166.0 – 180.0] 0.000 170.0 [163.0 – 180.0] 0.000 
Tumor size – Macro % 85.1 81.3 90.8 0.000 83.9 0.276 
Diabetes Mellitus – % 39.4 36.6 43.4 0.025 34.9 0.050 
IGF-I xULN before addition of PEGV
 
2.0 [1.5 – 2.7] 1.9 [1.5 – 2.6] 2.1 [1.6 – 2.8] 0.000 2.1 [1.5 – 3.2] 0.001 
GH before addition of PEGV – µg/l 7.9 [3.1 – 17.8] 8.4 [3.2 – 17.5] 7.5 [2.2 – 18.6] 0.617 5.9 [2.0 – 11.0] 0.000 
Previous treatment:       
   Surgery – total % 51.0 28.6 84.2 0.000 81.9 0.000 
         Once debulked – % 48.6 28.6 78.1  71.1  
         Twice debulked – % 2.4 N/A 6.1  8.4  
         ˃ Twice debulked – %  N/A N/A N/A  2.4  
   RTx – % 16.0 10.7 23.7 0.000 40.2 0.000 
Duration of LA-SSA before addition 
of PEGV – months 
16.0 [8.3 – 39.0] 12.0 [7.2 – 26.8] 25.0 [11.5 – 62.0] 0.000 34.4 [13.4 – 86.4] 0.000 
Outcome:        
Required PEGV dose – mg weekly 105.0 [65.0 – 200] 80.0 [60.0 – 120.0] 210.0 [105.0 – 280.0] 0.000 105.0 [105 – 140] 0.000 
Page 22 of 27
Variable  Estimate SE p-value 
Intercept 5.5994 0.9382 <0.0001 
IGF-I (xULN)* 0.2585 0.0459 <0.0001 
Weight (kg)*  -0.0365 0.0192 0.0830 
Weight
2 
(kg)* 0.0002 0.0001 0.0038 
Age at diagnosis (years) -0.0045 0.0033 0.1700 
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